Booth Jean, Clayton Tim, Pepper John, Nugara Fiona, Flather Marcus, Sigwart Ulrich, Stables Rodney H
Clinical Trials and Evaluation Unit, Royal Brompton Hospital, London, United Kingdom.
Circulation. 2008 Jul 22;118(4):381-8. doi: 10.1161/CIRCULATIONAHA.107.739144. Epub 2008 Jul 7.
The Stent or Surgery Trial is a randomized, controlled trial comparing percutaneous coronary intervention with coronary artery bypass grafting (CABG) for patients with multivessel disease. Initial results at a median follow-up of 2 years showed a survival advantage for patients randomized to CABG. This article reports survival outcome at a median follow-up of 6 years.
A total of 988 (n=488 percutaneous coronary intervention, n=500 CABG) patients were randomized at 53 centers during the period from 1996 to 1999. Investigators established survival status from hospital or community medical records or national databases or by direct contact with patients and their relatives. All-cause mortality was compared with hazard ratios and confidence intervals calculated from Cox proportional hazards models. Prespecified subgroup analyses for diabetes mellitus, angina grade, and angiographic severity of coronary disease at baseline were performed with tests for interaction. At a median follow-up of 6 years, 53 patients (10.9%) died in the percutaneous coronary intervention group compared with 34 (6.8%) in the CABG group (hazard ratio 1.66, 95% confidence interval 1.08 to 2.55, P=0.022). Little evidence was found that the treatment effect on mortality differed between subgroups according to baseline angina grade (interaction test P=0.52), the severity of coronary disease (P=0.92), or diabetic status (P=0.15).
At a median follow-up of 6 years, a continuing survival advantage was observed for patients managed with CABG, which is not consistent with results from other stent-versus-CABG studies.
支架或手术试验是一项随机对照试验,比较经皮冠状动脉介入治疗与冠状动脉旁路移植术(CABG)治疗多支血管病变患者的疗效。中位随访2年的初步结果显示,随机接受CABG治疗的患者具有生存优势。本文报告中位随访6年的生存结果。
1996年至1999年期间,共有988例患者(经皮冠状动脉介入治疗组488例,CABG组500例)在53个中心进行了随机分组。研究人员通过医院或社区医疗记录、国家数据库或直接与患者及其亲属联系来确定生存状况。将全因死亡率与根据Cox比例风险模型计算的风险比和置信区间进行比较。对基线时糖尿病、心绞痛分级和冠状动脉造影严重程度进行了预设亚组分析,并进行了交互作用检验。中位随访6年时,经皮冠状动脉介入治疗组有53例患者(10.9%)死亡,而CABG组有34例患者(6.8%)死亡(风险比1.66,95%置信区间1.08至2.55,P=0.022)。几乎没有证据表明,根据基线心绞痛分级(交互作用检验P=0.52)、冠状动脉疾病严重程度(P=0.92)或糖尿病状态(P=0.15),各亚组的治疗对死亡率的影响存在差异。
中位随访6年时,观察到接受CABG治疗的患者持续存在生存优势,这与其他支架与CABG对比研究的结果不一致。